Selected Publications

Naik S, Aplenc R, Baumeister SH, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble A, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velaquez Gill SI: International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv 9(23): 6047-6058, Dec 2025 Notes: doi: 10.1182/bloodadvances.2025017011.

Zwaan CM, Tasian SK, Aplenc R, Brodersen LE, Buldini B, Moreloose BD, Dworzak MN, Fogelstrand L, Gibson BE, Goemans BF, Hasle H, Hirsch BA, Kaspers GJ, Klusmann J, Kutny MA, Lehrnbecher T, Locatelli F, Meshinchi S, Petit A, Pigazzi M, Tierens A, Kolb EA, Reinhardt D, Tomizawa D, Cooper TM: Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel. Blood Page: blood.2024027904, Oct 2025 Notes: doi: 10.1182/blood.2024027904.

Vasileiadi E, Elgarten CW, Getz KD, Aplenc R, Fisher BT: Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients with Hematologic Malignancy. J Pediatric Infect Dis Soc. Oct 2025 Notes: doi: 10.1093/jpids/piaf091.

Zheng DJ, Hettinger G, Bender JD, Boulter AC, Cao L, Elgarten CW, Fisher BT, Gathers C, Huang YV, Ko J, Leger KJ, Li Y, Myers R, Narayan HK, Ortiz J, Seif AE, Vasileiadi E, Aplenc R, Getz KD: National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia. JAMA Oncol Page: e254365, Oct 2025 Notes: doi: 10.1001/jamaoncol.2025.4365.

Vasileiadi E, Elgarten CW, Getz KD, Aplenc R, Fisher BT: Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy. J Pediatric Infect Dis Soc 14(10), Oct 2025 Notes: doi: 10.1093/jpids/piaf091.

Seif AE, McDonough SL, Becker-Haimes EM, Oranges KE, Clerico D, Hartman J, Rodock K, Schwartz LA, Elgarten CW, Myers RM, Puszczynski RO, Rheingold SR, Stern JW, Jubelirer TF, Armideo EA, Evageliou NF, Randall RJ, Bernt KM, Reilly AF, Tasian SF, Diamant RK, Fisher BT, Getz KD, Aplenc R: AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy. JCO Oncol Pract Page: OP2500314, Sept 2025 Notes: doi: 10.1200/OP-25-00314.

Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD: Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst Page: djaf234, Aug 2025 Notes: doi: 10.1093/jnci/djaf234.

Huang BL, Meyer LK, Alonzo TA, Wang Y, Lamble AJ, Ries RE, Wang W, Hirsch B, Raca G, Ma X, Gamis AS, Aplenc R, Kolb EA, Cooper TM, Tarlock K, Loken MR, Meshinchi S, Chewning JH, Woods WG, Horan JT: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. J Clin Oncol 43(17): 1961-1971, Jun 2025 Notes: doi: 10.1200/JCO-24-01841.

Newman H, Lee SHR, Polonen P, Shraim R, Li Y, Liu H, Aplenc R, Bandyopadhyay S, Chen C, Devidas M, Diorio C, Dunsmore K, Elghawy O, Elhachimi A, Fuller T, Gupta S, Hall J, Hughes AD, Hunger SP, Loh ML, Martinez Z, McCoy MF, Mullen CG, Pounds SB, Raetz E, Seffernick AE, Shi G, Sussman J, Tan K, Uppuluri L, Vincent TL, Wang'ondu R, Winestone LE, Winter SS, Wood BL, Wu G, Xu J, Yang W, Mullighan CG, Yang JJ, Bona K, Teachey DT: Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia. Blood Cancer Discov May 2025 Notes: doi: 10.1158/2643-3230.BCD-25-0049.

Myers RM, DiNofia AM, Li Y, Diorio C, Liu H, Wertheim G, Fraietta JA, Gonzalez V, Plesa G, Siegel DL, Iannone E, Shinehouse L, Brogdon JL, Taylor C, Jadlowsky JK, Hexner EO, Engels B, Baniewicz D, Callahan C, Ruella M, Aplenc R, Leahy AB, McClory SE, Rheingold SR, Wray L, June CH, Maude SL, Frey NV, Grupp SA: CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. J Immunother Cancer 13(4): e011549, Apr 2025 Notes: doi: 10.1136/jitc-2025-011549.